1-(4-(4-(1H-Tetrazol-5-yl)phenoxy)butyl)pyrimidine-2,4(1H,3H)-dione

ID: ALA4783647

PubChem CID: 162666203

Max Phase: Preclinical

Molecular Formula: C15H16N6O3

Molecular Weight: 328.33

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=c1ccn(CCCCOc2ccc(-c3nnn[nH]3)cc2)c(=O)[nH]1

Standard InChI:  InChI=1S/C15H16N6O3/c22-13-7-9-21(15(23)16-13)8-1-2-10-24-12-5-3-11(4-6-12)14-17-19-20-18-14/h3-7,9H,1-2,8,10H2,(H,16,22,23)(H,17,18,19,20)

Standard InChI Key:  DYBOCUOZDDPZFL-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   17.5532   -5.9205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.2662   -6.3263    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.2701   -7.1435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5650   -7.5548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8561   -7.1490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8481   -6.3318    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.5494   -5.1033    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.9790   -7.5452    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.1392   -5.9301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4341   -6.3415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7252   -5.9398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0201   -6.3511    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3071   -5.9494    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.6020   -6.3607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8931   -5.9590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1880   -6.3704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1918   -7.1875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9048   -7.5934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6099   -7.1779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7403   -7.2718    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1984   -7.8835    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.6097   -8.5886    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.4064   -8.4142    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.4867   -7.5989    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  1  6  1  0
  1  7  2  0
  3  8  2  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 14 19  2  0
 13 14  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 20 24  1  0
 17 24  1  0
 12 13  1  0
  6  9  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4783647

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 328.33

Molecular Weight (Monoisotopic): 328.1284

AlogP: 0.58

#Rotatable Bonds: 7

Polar Surface Area: 118.55

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 4.33

CX Basic pKa: ┄

CX LogP: 0.87

CX LogD: -0.73

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.61

Np Likeness Score: -1.59

References

1. Shekouhy M,Karimian S,Moaddeli A,Faghih Z,Delshad Y,Khalafi-Nezhad A.  (2020)  The synthesis and biological evaluation of nucleobases/tetrazole hybrid compounds: A new class of phosphodiesterase type 3 (PDE3) inhibitors.,  28  (12): [PMID:32503691] [10.1016/j.bmc.2020.115540]

Source

Source(1):

• Scientific Literature